SEATTLE, March 28 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today announced that the filing of its annual report on Form 10-K for the year ended December 31, 2007 has now been timely completed. This filing is available for review on CTI's Web site at http://www.CellTherapeutics.com or on the Securities and Exchange Commission's Web site at http://www.sec.gov.
As required under Nasdaq Marketplace Rule 4350(b)(1)(B), CTI also announced that its independent auditor's report included in the annual report on Form 10-K contains a "going concern" qualification.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed
to developing an integrated portfolio of oncology products aimed at making
cancer more treatable. For additional information, please visit
|SOURCE Cell Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved